Investor Foresite Capital Fund II, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Foresite Capital Fund II, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2020-06-12 13G/A AERI / Aerie Pharmaceuticals Inc 5,524,591 837,907
2020-02-14 13G/A AERI / Aerie Pharmaceuticals Inc 5,133,691 5,524,591
2020-02-14 13G/A 0HBB / Aimmune Therapeutics Inc 3,678,471 0
2019-08-15 13G/A AERI / Aerie Pharmaceuticals Inc 3,885,014 5,133,691
2019-02-13 13G/A AERI / Aerie Pharmaceuticals Inc 3,623,191 3,885,014
2019-02-13 13G/A ALDR / Alder BioPharmaceuticals, Inc. 4,147,871 4,528,350
2019-02-13 13G/A 0HBB / Aimmune Therapeutics Inc 3,864,970 3,678,471
2018-02-13 13G/A AERI / Aerie Pharmaceuticals Inc 3,173,201 3,623,191
2018-02-13 13G/A OREX / Orexigen Therapeutics, Inc. 971,385 0
2018-02-13 13G/A ALDR / Alder BioPharmaceuticals, Inc. 4,147,871
2018-02-13 13G/A NSTG / NanoString Technologies, Inc. 1,117,166 0
2018-02-13 13G/A 0HBB / Aimmune Therapeutics Inc 4,739,720 3,864,970
2018-02-13 13G/A QURE / uniQure N.V. 1,694,582 744,584
2017-11-03 13G QURE / uniQure N.V. 1,694,582
2017-02-14 13G/A LRMR / Larimar Therapeutics, Inc. 2,588,110 1,133,184
2017-02-14 13G/A NVET / Nexvet Biopharma plc 1,074,001 1,094,695
2017-02-14 13G/A 0HBB / Aimmune Therapeutics Inc 4,442,920 4,739,720
2017-02-14 13G/A AERI / Aerie Pharmaceuticals Inc 1,336,443 3,173,201
2017-02-14 13G/A OREX / Orexigen Therapeutics, Inc. 11,225,049 971,385
2017-02-14 13G/A NSTG / NanoString Technologies, Inc. 1,162,357 1,117,166
2016-07-18 13G NSTG / NanoString Technologies, Inc. 1,162,357
2016-02-19 13G AERI / Aerie Pharmaceuticals Inc 1,336,443
2016-02-12 13G/A OREX / Orexigen Therapeutics, Inc. 11,225,049
2016-02-12 13G/A SCYX / SCYNEXIS, Inc. 337,177
2016-02-12 13G/A LRMR / Larimar Therapeutics, Inc. 1,487,300 2,588,110
2016-02-12 13G/A NVET / Nexvet Biopharma plc 1,074,001
2016-02-12 13G/A 0HBB / Aimmune Therapeutics Inc 4,417,435 4,442,920
2016-02-05 13G RGLS / Regulus Therapeutics Inc. 2,729,971 2,648,808
2016-02-05 13G/A RGLS / Regulus Therapeutics Inc. 2,729,971 2,469,666
2015-10-23 13G LRMR / Larimar Therapeutics, Inc. 1,487,300
2015-09-09 13G RGLS / Regulus Therapeutics Inc. 2,729,971
2015-08-14 13G 0HBB / Aimmune Therapeutics Inc 4,417,435
2015-02-11 13G SCYX / SCYNEXIS, Inc. 662,945
2015-02-11 13G NVET / Nexvet Biopharma plc 908,333